ORIGINAL ARTICLE


Open Access Peer-Reviewed

0

View

Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression

Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression

Olivia M. Dean1,2,3, Alyna Turner1,4, Gin S. Malhi5,6, Chee Ng7, Sue M. Cotton8,9, Seetal Dodd1,3, Jerome Sarris3,10, Yuval Samuni1, Michelle Tanious5,6, Nathan Dowling7, Astrid Waterdrinker1, Deidre Smith7, Michael Berk1,2,3,8

Vol.37 Issue 1/2015:

1. IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Australia
2. Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
3. University of Melbourne, Melbourne, Australia
4. University of Newcastle, Newcastle, Australia
5. Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, Australia
6. Department of Psychiatry, CADE Clinic, Sydney, Australia
7. Department of Psychiatry University of Melbourne, Melbourne, Australia
8. Orygen Youth Health Research Centre, Melbourne, Australia
9. Centre of Youth Mental Health, University of Melbourne, Melbourne, Australia
10. Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, Australia Corresponding author
Michael Berk
IMPACT SRC, School of Medicine, Deakin University
P.O. Box 281, 3220
Geelong, VIC, Australia
E-mail: mikebe@barwonhealth.org.au

© 2026 All rights reserved